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Abstract: Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as 
eczematous lesions, often associated with allergic rhinitis and asthma. Historically, moderate-
to-severe disease has been managed with systemic immunosuppression, such as oral cortico-
steroids, which result in relapse and limiting side effects. Due to recent advancements in the 
identification of interleukin (IL)-4 and IL-13 as key mediators in AD, new biological agents 
have been developed for treatment. Dupilumab is a recently approved monoclonal antibody 
that targets the alpha subunit of the IL-4 receptor and, thus, downregulates activity of IL-4 and 
IL-13. This review discusses the profile of dupilumab and its potential for efficacy and safety 
in treating moderate-to-severe AD by reviewing data from Phase I–III clinical trials. Results 
suggest that dupilumab shows great therapeutic promise for AD. Further studies investigating 
extended use of dupilumab and dupilumab in comparison to other agents are needed to establish 
long-term efficacy and safety.
Keywords: atopic dermatitis, dupilumab, IL-4, IL-13, biologics
Background
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by 
erythema, pruritus, and scaling of skin. AD is clinically diagnosed by these essential 
features, and the diagnosis is supported by early age of onset, personal or family history 
of atopy, and xerosis.1 AD has a complex, heterogeneous etiology that includes barrier 
defects, intrinsic immunological hyperactivity, and extrinsic triggers.2,3 According to a 
recent study of lifetime worldwide AD prevalence over the period of 1990–2010, there 
is no overall global trend in the prevalence of AD.4 However, a steady increase in AD 
prevalence in developing countries has been observed. In general, AD is estimated 
to affect up to 20% of children in developed countries and 3% of adults worldwide, 
with up to 50% of pediatric AD cases persisting into adulthood.5,6 In the USA, 10.7% 
of children and 3.2% of adults are living with AD.7,8
For patients with moderate-to-severe AD, skin lesions encompassing large sur-
face areas are often associated with severe itching. These lesions can cause sleep 
disturbances and, in turn, symptoms of anxiety, depression, and poor quality of life.9 
Topical steroids, topical immunomodulators, and phototherapy are often inadequate 
in providing sustained improvement in these patients, despite the additive benefit of 
topicals in decreasing inflammation and restoring epidermal barrier function.2 For 
patients with poor response to these topicals, the mainstay of treatment is systemic 
immunosuppression, including oral corticosteroids, cyclosporine, or mycophenolate 
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mofetil. Though these medications may provide moderate 
relief in AD, the risks often outweigh the benefits of long-
term use. In particular, these oral agents are associated with 
significant side effects such as increased infections, nausea/
vomiting, hypertension, and headaches.10,11 In a 10-year chart 
review of the use of oral immunosuppressive drugs in patients 
with severe AD, frequent reasons for discontinuation of 
these therapies included ineffectiveness and adverse events, 
such as neurological symptoms, gastrointestinal upset, and 
fatigue/flu-like symptoms.11 Furthermore, for patients with 
renal impairment and uncontrolled hypertension, oral corti-
costeroids, mycophenolate mofetil, and cyclosporine are less 
viable treatment options due to their high risk to exacerbate 
the underlying comorbidities.
Given the poor therapeutic responses, inconveniences, 
and therapy-limiting side effects of conventional systemic 
AD therapeutics, there is a substantial unmet need for more 
efficacious and promising agents for moderate-to-severe AD 
with minimal adverse effects. With recent advances in the 
understanding of the pathological mechanisms of AD, new 
biological agents have been developed and are being evalu-
ated in clinical trials. In March 2017, dupilumab became 
the first biologic to be approved by the US Food and Drug 
Administration for inadequately controlled moderate-to-
severe AD.12 The drug received this approval because of its 
significant demonstration of efficacy and safety in treating 
AD in three randomized Phase III pivotal trials. The pur-
pose of this article is to review the findings on dupilumab 
in clinical trials and examine the potential of the drug for 
inadequately controlled moderate-to-severe AD.
Methods
Relevant articles on disease activity in AD and clinical trials 
of dupilumab were searched and selected from the databases 
of PubMed and ClinicalTrials.gov using the following terms: 
dupilumab, AD, disease activity, interleukin (IL)-4, IL-13, 
thymus and activation-regulated chemokine (TARC), eotaxin 
3 (CCL26), comorbidity, quality of life, efficacy, biologic, 
and adverse effects. Additional publications were collected 
from references identified in articles and related citations in 
PubMed. As of June 2017, Phase I, II, and III clinical trials of 
dupilumab have been published. In total, 31 relevant papers 
were reviewed and referenced.
Results
Pathogenesis and disease activity in AD
Ongoing debates regarding the pathogenesis of AD have 
led to the following description of two forms of the disease: 
1) the intrinsic form resulting from abnormal epidermal 
structure and function, and 2) the extrinsic form due to 
cutaneous inflammation caused by immune responses to 
extrinsic  antigens.13,14 Moreover, there has been identifica-
tion of increased activity of T lymphocytes secreting effector 
cytokines and dysregulation of both cell-mediated immune 
responses and inflammatory cascades in AD skin.13 Yet, over 
the past several years, attention has been turned specifically 
toward type 2 inflammatory mediators as targets for AD 
therapy.
In particular, IL-4 and IL-13, cytokines from T helper type 
2 (Th2) cells, are key mediators of the inflammation in AD. 
These cytokines upregulate the expression of chemokines 
such as TARC and CCL26.10,15–18 This increased expression 
of TARC and CCL26 relates to increased disease activity, 
including the selective migration of Th2 lymphocytes and 
eosinophils into AD lesions, which cause inflammation.15–18 
Additionally, in synergy with Toll-like receptor 2 ligands, 
IL-4 potentiates the chronicity of AD through IL-4-mediated 
suppression of IL-10.19 IL-4 and IL-13 also decrease the 
keratinocyte expression of barrier proteins, such as filaggrin, 
involucrin, and loricrin, triggering epidermal hyperplasia.20,21 
Additional effects of these cytokines on keratinocytes 
include the suppression of keratinocyte differentiation and 
the synthesis of antimicrobial peptides and lipids.13,22,23 This 
activity further disrupts the skin barrier through aberrant 
expression of human β-defensins (hBD-2 and hBD-3) and 
cathelicidin (LL-37) leading to an increase in the suscepti-
bility of lesional skin to infection by microorganisms, such 
as Staphylococcus aureus.13,24,25 Moreover, IL-4 and IL-13 
induce B-cell differentiation leading to immunoglobulin E 
(IgE) class switching.26 This phenomenon explains the eleva-
tion of IgE levels in AD, which is often associated with the 
extrinsic form of the disease.10,27,28 Given that both IL-4 and 
IL-13 act through a common receptor (IL-4 receptor alpha; 
IL-4Rα), IL-4Rα has become a target of interest in treating 
AD. Inhibition of IL-4Rα has resulted in normalization of 
skin gene expression from lesional toward nonlesional skin, 
reduction of TARC expression, and efficacy in the suppres-
sion of itch.10,28–30
Dupilumab: mechanism of action
Dupilumab is a fully human monoclonal antibody that binds 
to the IL-4Rα, resulting in inhibition of both IL-4 and IL-13 
signaling.10,12 This blockade by dupilumab reduces the type 2 
helper T-cell-mediated inflammation cascade in AD. Specifi-
cally, competitive inhibition at the IL-4Rα inhibits activa-
tion of the signal transducer and activator of transcription 
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6 (STAT6)/Janus kinase 1 (JAK1) signaling cascade (Fig-
ure 1).31,32 Overexpression of STAT6 has been demonstrated 
to decrease epidermal differentiation complex genes, such as 
the genes for loricrin and involucrin, and enhance penetration 
of pathogens across the skin barrier leading to AD-like skin 
disease in mice models.20,33
Dupilumab: Phase I trials
In two 4-week randomized, double-blind, placebo-controlled, 
dose-increasing Phase I trials, dupilumab was evaluated as 
a monotherapy for moderate-to-severe AD in adults.28,34 In 
the M4A trial, 30 subjects received 75, 150, or 300 mg of 
subcutaneous dupilumab or placebo weekly for 4 weeks. The 
subjects were randomly assigned to receive placebo or dupil-
umab in a 1:4 ratio. In the M4B trial, 37 subjects were studied 
with 150 or 300 mg of subcutaneous dupilumab or placebo 
weekly for 4 weeks. These subjects were also randomized 
to receive placebo or dupilumab, but in a 1:3 ratio. Both the 
M4A and M4B trials were designed to assess safety as the 
primary end point. From composite analysis of both studies, 
by day 29, 59% of patients receiving dupilumab showed 50% 
reduction in the Eczema Area and Severity Index (EASI) 
score (EASI-50) compared to 19% of the placebo group 
(Table 1). In addition, significant improvements in Investiga-
tor Global Assessment (IGA) scores and pruritus scores for 
all dupilumab doses combined were observed in both studies. 
Concerning safety data, nasopharyngitis and headache were 
the most common side effects with no evidence of serious 
adverse events in either trial.28,34
In addition to clinical improvement and safety, gene 
expression profiles of lesional sites after 150 and 300 mg 
dupilumab shifted to a more nonlesional molecular phenotype 
within 4 weeks.34,35 Lesional skin showed overall improve-
ment in transcriptome by 24% in the 150 mg dose group and 
49% in 300 mg dose group compared to 21% in the placebo 
group.28,34 Notably, markers of epidermal  proliferation 
Figure 1 Receptor signaling for IL-4 and IL-13.
Notes: In hematopoietic cells, binding of IL-4 to type I IL-4Rα induces heterodimerization with γC, which activates JAK kinases and leads to the phosphorylation of 
STAT6. Similarly, in nonhematopoietic cells, such as keratinocytes, hair follicles, and epithelial/smooth muscle cells, STAT6 is phosphorylated by the induction of the 
heterodimerization of type II IL-4Rα and IL-13Rα1 after binding of the IL-4 or IL-13 to their respective receptors. Of note, IL-13 may bind to IL-13Rα2; however, this 
receptor lacks a signaling motif. Dupilumab binds the IL-4R subunit of both type I and type II IL-4 receptors leading to inhibition of the JAK/STAT signaling cascade.
Source: Copyright 2014. Dove Medical Press. Reproduced from Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma 
Allergy. 2014;7:123–130.32
Abbreviations: IL, interleukin; IL-4Rα, IL-4 receptor alpha subunit; IL-13α1, IL-13 receptor alpha 1 subunit; IL-13α2, IL-13 receptor alpha 2 subunit; JAK, Janus kinase; 
STAT, signal transducer and activator of transcription.
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(K16 and K6B, which reduced epidermal hyperplasia) were 
downregulated by dupilumab.34,35 T-cell markers and other 
inflammatory mediators, such as chemokines, were also 
downregulated by dupilumab. Dupilumab also upregulated 
genes related with skin barrier functions such as structure-
related gene, MATN4, lipid-metabolism-related genes, 
PLIN4, ADIPOQ, and PLIN1, and barrier-related function 
genes, CLDN8, ELN, and CLDN11.35
Dupilumab: Phase IIa trials
In a 12-week-long monotherapy study, M12, dupilumab 
demonstrated significant improvement in reduction of 
involvement and severity of AD in adults with moderate-to-
severe disease. In the M12 study, subjects were randomized 
to receive subcutaneous 300 mg dupilumab (n=55) or placebo 
(n=54) weekly for 12 weeks. Dupilumab resulted in substan-
tial improvement in multiple clinical measures in EASI-50, 
EASI-75, and IGA scores (Table 1), and pruritus numerical 
rating scale (NRS) score by day 85. Of note, 85% of patients 
on dupilumab achieved EASI 50 compared to 35% in the 
placebo group. Overall, pruritus NRS scores decreased by 
56% in the dupilumab group compared to 15% in the placebo 
group. Serum TARC and serum IgE levels also decreased 
significantly more in dupilumab patients.28,34
In a 4-week-long randomized, double-blind, parallel-
group, placebo-controlled clinical trial (C4), dupilumab was 
also evaluated in combination with topical corticosteroids 
(TCSs). Subjects were randomized in a 2:1 ratio to receive 
subcutaneous 300 mg dupilumab (n=21) or placebo (n=10) 
weekly for 4 weeks in combination with a regimen of TCSs. 
The primary end points were the occurrence and severity 
of adverse events. All subjects in the dupilumab plus TCS 
group achieved EASI-50 by 4 weeks, while only 50% in 
the placebo plus TCS group achieved the same (Table 1).28 
Again, the dupilumab group showed significant improvement 
in pruritus NRS and IGA scores compared to the placebo 
group. Moreover, the dupilumab group used 50% less TCSs 
in comparison to the placebo group. There was also a greater 
decline of TARC and IgE levels in the dupilumab group.28,34 In 
the combined safety data for studies of M4A, M4B, M12, and 
C4, adverse events occurred at similar rates in the dupilumab 
and placebo groups.34
Dupilumab: Phase IIb trial
In an international, multicenter, randomized, double-blind, 
dose-ranging, placebo-controlled clinical trial, the efficacy 
and safety of five different dosings of dupilumab were 
evaluated over a period of 16 weeks. Subjects were  randomly T
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assigned to receive subcutaneous placebo (n=61) or dupil-
umab 100 mg (n=65) monthly, 300 mg (n=65) monthly, 200 
mg (n=61) every 2 weeks, 300 mg (n=64) biweekly, and 
300 mg (n=63) weekly. By week 16, dupilumab showed 
improved EASI scores and resulted in significant improve-
ment in SCORAD (Scoring Atopic Dermatitis) scores in a 
dose-dependent manner (Table 1). All of the 300 mg dupil-
umab dose regimens resulted in more than 3 points decrease 
in pruritus NRS scores in 37%–54% of subjects versus 8% 
of subjects in the placebo group. Furthermore, dupilumab 
resulted in early and sustained improvement in depression, 
anxiety, and quality-of-life scores. Mean percentage changes 
in TARC at week 16 correlated with clinical outcomes such 
as EASI, SCORAD, and IGA scores.29
Dupilumab: Phase III trials
In 2016, two identically designed Phase III trials of dupilumab 
were carried out for subjects with moderate-to-severe AD. 
Subjects were randomly assigned in a 1:1:1 ratio to receive, 
subcutaneous 300 mg dupilumab or placebo weekly or the 
same dose of dupilumab every other week alternating with 
placebo for 16 weeks. The primary outcome was the propor-
tion of subjects who had both a score of 0 or 1 (clear or almost 
clear) on IGA and a reduction of 2 points or more in that score 
from baseline at week 16. Over 600 patients participated in 
each trial, with 671 subjects for SOLO 1 and 708 subjects 
for SOLO 2 randomized to receive dupilumab or placebo. In 
SOLO 1, the primary outcome point was achieved by 38% 
of patients receiving dupilumab every other week, 37% of 
those receiving dupilumab weekly, and 10% of subjects who 
received placebo (Table 2). SOLO 2 demonstrated comparable 
results, with 36% of patients in both dupilumab groups and 
8% of the placebo group reaching the primary outcome point. 
Additionally, those in the placebo group received more rescue 
treatment than those in the dupilumab groups.30
In both trials, dupilumab significantly decreased patient-
reported symptoms of AD, with improvement in sleep, 
anxiety, depression, and, therefore, quality of life of subjects. 
In Dermatology Life Quality Index (DLQI) and Patient-
Oriented Eczema Measure (POEM) scores, dupilumab 
groups demonstrated twice as much improvement compared 
to placebo groups. At week 16, among the subjects who had 
Hospital Anxiety and Depression Scale (HADS)-Anxiety or 
HADS-Depression scores ≥8 at baseline, significantly more 
dupilumab-treated subjects had HADS scores of <8 compared 
to the placebo group.30
In a 1-year-long randomized, double-blinded, placebo-
controlled clinical trial (LIBERTY AD CHRONOS), T
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Awosika et al
 dupilumab was evaluated as concomitant therapy with 
TCSs in adults with moderate-to-severe AD and inadequate 
response to TCSs alone.12 Subjects were randomized in a 
3:1:3 ratio to receive subcutaneous 300 mg dupilumab weekly 
(n=319), 300 mg dupilumab every 2 weeks (n=106), or pla-
cebo (n=315), with all three groups receiving concomitant 
TCSs with or without topical calcineurin inhibitors (TCI) 
tapered, discontinued, or restarted on the basis of disease 
activity. By week 16, 39% of patients in each dupilumab 
group achieved the coprimary endpoint of IGA 0/1 compared 
to 12% in the placebo group (Table 2). The other coprimary 
endpoint of 75% reduction in EASI score (EASI-75) was 
achieved by 64% of the weekly dupilumab group, 69% of the 
dupilumab every other week group, and 23% of the placebo 
group. Overall, patients receiving dupilumab had more days 
free of TCSs/TCI and/or systemic rescue medication use 
than those in the placebo group at 16 weeks and 52 weeks. 
Additionally, corresponding SCORAD, POEM, HADS, and 
DLQI scores were significantly reduced in the dupilumab 
groups compared to the placebo group.12 Improvement of 
NRS and DLQI scores in all three Phase III trials for dupil-
umab patients is demonstrated in Figures 2 and 3.12,30
Discussion
Literature concerning the impact of dupilumab in the patho-
genesis of AD includes Phase I, II, and III clinical trials. 
Results from these trials show that dupilumab improves clini-
cal symptoms of moderate-to-severe AD and decreases T-cell 
markers, markers of epidermal proliferation, and inflammatory 
mediators and chemokines.28 In particular, compared to pla-
cebo and lower doses, the 300 mg dose of dupilumab dem-
onstrated the greatest improvement in EASI and NRS scores, 
and transcriptome of lesional skin in Phase I and II studies.28,34 
Moreover, the 300 mg dose every other week resulted in similar 
Figure 2 Percentage of patients who achieved peak pruritus numerical rating scale score improvement ≥4 points from baseline in Phase III trials.
Abbreviations: AD, atopic dermatitis; TCS, topical corticosteroid.
0 10 20 30 40 50 60 70
Week 16 phase III LIBERTY AD
CHRONOS trial
Week 52 phase III LIBERTY AD
CHRONOS trial
Week 16 SOLO 1
Week 16 SOLO 2
Dupilumab every other week
Dupilumab weekly
Placebo
Dupilumab + TCS every other week
Dupilumab + TCS weekly
Placebo + TCS
Figure 3 Least squares mean change in Dermatology Life Quality Index score from baseline in Phase III trials.
Abbreviations: AD, atopic dermatitis; TCS, topical corticosteroid.
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CHRONOS trial
Week 52 phase III LIBERTY AD
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Dupilumab review of the literature
efficacy to the 300 mg weekly dose in achieving primary and 
secondary outcome measures in Phase III trials.12,30 Notably, 
the greatest percentage of patients achieved improvement in 
EASI or IGA when dupilumab was administered at 300 mg 
every other week with concomitant TCS use.12
Additionally, the frequency of adverse events was demon-
strated to be similar between placebo and dupilumab groups, 
with the most commonly reported adverse events including 
headaches and nasopharyngitis in Phase I and II trials.28 
In comparison, the most common adverse events reported 
in Phase III trials were exacerbations of AD (10%–18%), 
injection-site reactions (15%–19%), and nasopharyngitis 
(10%–23%), with conjunctivitis also occurring in 14% or 
more of patients on dupilumab in the 1-year-long Phase III 
trial.12,30 Of note, in Phase I and II trials dupilumab also dem-
onstrated decreased total number of skin infections compared 
to placebo (4%–5% versus 10%–24%).28 Moreover, across 
the four Phase I and II trials, the rate of skin infections in 
the placebo groups was 0.2 per patient compared to 0.05 
infections per patient in the dupilumab groups.28 This par-
ticular finding supports the concept that dupilumab improves 
epidermal barrier function.
In addition to its clinical efficacy, dupilumab also dem-
onstrated improved quality of life as well, with significant 
reduction of DLQI and POEM scores.30 Overall, these results 
suggest that IL-4 and IL-13 are important mediators in the 
pathogenesis and morbidity of AD. However, additional trials 
over an extended period of time are necessary to establish a 
long-term safety and efficacy profile of dupilumab.
The recent recognition of AD as a predominantly Th2-
mediated disease has led the way for the investigation of 
a variety of therapeutics that target specific inflammatory 
mediators involved in innate immunity. Multiple biologics 
are currently being investigated in clinical trials, including 
antibodies that specifically target IL-13, IL-17, IL-22, IL-31, 
and IL-12/IL-23p40.36 Topical and oral phosphodiesterase-4 
inhibitors are also being investigated in Phase II and Phase 
III clinical trials, along with a JAK inhibitor and therapeutics 
targeting thymic stromal lymphopoietin and chemoattractant 
receptor-homologous molecule expressed on Th2 cells.36 
These novel therapies have shown promising results. Notably, 
IL-31 inhibition has shown significant reduction of pruritus 
in patients with AD.37 Yet, despite these ongoing investiga-
tions into the use of multiple biologics for treatment of AD, 
dupilumab remains the first and only biologic to be approved 
for moderate-to-severe AD.
Prior to the development of dupilumab, treatments 
 available for AD included topical and oral glucocorticoids, 
calcineurin inhibitors, cyclosporine, methotrexate, azathio-
prine, and mycophenolic acid precursors. Currently, there 
are no studies comparing dupilumab to other systemic treat-
ments approved for AD. However, prior to the approval of 
dupilumab, a systematic review of 34 randomized control 
trials involving 1,653 patients compared the efficacy and 
safety of 12 systemic treatments using the Grading of Rec-
ommendations Assessment, Development, and Evaluation 
approach.38 Azathioprine and methotrexate were recom-
mended as second- and third-line treatments, respectively, 
according to moderate-quality evidence.38 Cyclosporine A 
(CsA) received the strongest recommendation as a first-line 
treatment for short-term use in AD. Additionally, evidence 
based on four trials demonstrated that long-term treatment 
with CsA can be recommended for up to 1 year.38–42 However, 
comparison of associated risks of long-term use of CsA, such 
as nephrotoxicity and hypertension, to that of year-long use of 
dupilumab, such as nasopharyngitis and conjunctivitis, sug-
gests that dupilumab is likely a safer long-term option.12,39–43 
Yet, due to variations in trial designs, it is problematic to 
compare safety and efficacy data between studies of systemic 
treatments and dupilumab.29,38
Future evaluations should focus on comparing the effi-
cacy and safety of dupilumab against available systemic 
treatments in head-to-head trials. In addition, further studies 
observing the long-term efficacy and safety of dupilumab are 
also needed. In particular, extended observation to assess 
immunogenicity is warranted. Specifically, an assessment of 
the development of neutralizing antibodies over long-term 
use may provide further insight into how immunogenicity 
may affect long-term efficacy of dupilumab. Overall, the 
administration of dupilumab every other week and its rela-
tive safety and efficacy offer a convenient and lower-risk 
alternative to currently available systemic treatments for 
moderate-to-severe AD.
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